1. Home
  2. MCRB vs SWKH Comparison

MCRB vs SWKH Comparison

Compare MCRB & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$17.19

Market Cap

162.7M

Sector

Health Care

ML Signal

HOLD

Logo SWK Holdings Corporation

SWKH

SWK Holdings Corporation

HOLD

Current Price

$17.42

Market Cap

175.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCRB
SWKH
Founded
2010
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Financial Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
162.7M
175.5M
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
MCRB
SWKH
Price
$17.19
$17.42
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$14.33
$18.00
AVG Volume (30 Days)
323.3K
12.6K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
120.89
EPS
0.62
1.85
Revenue
$351,000.00
$40,149,000.00
Revenue This Year
N/A
$52.93
Revenue Next Year
N/A
N/A
P/E Ratio
$28.23
$9.26
Revenue Growth
N/A
62.38
52 Week Low
$6.53
$13.17
52 Week High
$29.98
$20.49

Technical Indicators

Market Signals
Indicator
MCRB
SWKH
Relative Strength Index (RSI) 49.93 59.24
Support Level $16.61 $16.69
Resistance Level $18.86 $17.75
Average True Range (ATR) 3.42 0.30
MACD -0.19 0.03
Stochastic Oscillator 11.70 58.50

Price Performance

Historical Comparison
MCRB
SWKH

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Share on Social Networks: